vjtweet Posted - 3 days ago

$NAMS acting good.. should move up if the mkt condition is good. Don't rush to buy anything yet.. let some run away.

DrBenGalper Posted - 5 days ago

$ESPR Bempedoic acid & Ezetimibe is Nexlizet to be clear, Reduction of LDL-c is 40 to 45%. Nexlizet will generate billions. Get regular blood work checked every six months to establish a baseline. This regular monitoring helps detect any early signs of metabolic or cardiovascular issues like pre-diabetes and provides a clear picture of the patient’s health status. It's essential for tailoring the right treatment. I researched the $NAMS drug, the Broadway trials showed a 35% LDL reduction but now show 33% this is good, but NO CRP reduction. Insurance won't cover the cost for years after approval. 2027 approval. Nexlizet is still my choice

coloradoriley Posted - 5 days ago

$NAMS high and tight. love the recent uptick in vol

JFDI Posted - 5 days ago

$NAMS weekly base

Doozio Posted - 6 days ago

$NAMS obviously INTA 🧠⏰♾️

JFDI Posted - 6 days ago

$NAMS good lookin bar. Moving averages still need to catch up.

profitsforall Posted - 6 days ago

$NAMS Enjoy the NAMS stock price while you can, because IMHO it isn't going to last.....WAY Overpriced for where it is in it's product life cycle...way ahead of itself.

newfguy Posted - 6 days ago

$NAMS look at al the bag holders crying their siren songs while NAMS sails on by with the winds filling its sails

profitsforall Posted - 6 days ago

$ESPR $NAMS If you look at the current Stock Prices of NAMS and ESPR, which one has the MOST UPSIDE....In my opinion not even close - ESPR

Canyon_Partnerrs Posted - 6 days ago

$ESPR $NAMS Drug no hs-CRP reduction, unlike ESPERION THERAPEUTICS NEXLIZET & NEXLETOL that drop hs-CRP levels by 25%. ESPR should be trading above $AMC levels & so many other stocks. My $BBAI & $SOUN have done better than ESPR yet ESPR has more earnings power by selling the only statin alternative drugs with primary prevention labels. 20 million Americans need statin alternative medications.

Barbell_Investment_Ideas Posted - 6 days ago

$NAMS totally nonsensical share price development ... price targets from the sell-side are now above 50$, institutional investors are insanely eager to get a piece of the pie at a price above the current share price ... but retail drives down the price ... lol ... im patient with my warrants ;)

Quantumup Posted - 6 days ago

Cantor Fitzgerald🏁 $ESPR Overweight; $8, says "we are initiating coverage of Esperion Therapeutics (ESPR) with an OW rating, 12-month PT of $8." $nams "The company markets the oral ATP-citrate lyase (ACLY) inhibitors, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid + ezetimibe), for LDL-C lowering and cardiovascular risk reduction. Shares have been down recently on competitive concerns from NAMS's (NC) CETP inhibitor, obicetrapib, which recently had positive Phase 3 data. However, we believe investors are missing the fact that NEXLETOL/NEXLIZET work in a validated pathway and have well-characterized effects on lipid metabolism (while it's unclear how obicetrapib will perform in an outcomes trial). This creates an attractive entry position for investors at this valuation; shares are currently trading at <0.5% potential peak revenues."

newfguy Posted - 1 week ago

$NAMS the ESPR dreamers are wetting the bed

Scanners_Free Posted - 1 week ago

$NAMS PASHE 3 NEWS

scriptstrend2024 Posted - 1 week ago

$ESPR $NAMS $AMGN $REGN Key Comparisons Between ESPR and NAMS Efficacy and Mechanism: NAMS (Obicetrapib): Achieves ~33% LDL-C reduction with statin co-administration. It does not significantly impact hs-CRP levels, which are linked to inflammation and cardiovascular risk. Esperion (Nexletol/Nexlizet): Lowers LDL-C by 25–50%, depending on patient specifics, and also reduces hs-CRP by 25%. It is the only statin-alternative therapy with a primary prevention label. Regulatory and Commercial Timelines: NAMS’s obicetrapib is still years from approval (expected late 2027) and may face further delays Esperion’s Nexletol and Nexlizet are already FDA-approved and gaining traction in the market, including new international markets. Pricing and Accessibility: Obicetrapib's projected price may exceed that of Nexletol, potentially limiting its early adoption. Esperion's affordability and established position could maintain its competitive advantage. Esperion's fair valuation is $1.48 billion.

ChartLaboratory_com Posted - 1 week ago

📈 $NAMS (NewAmsterdam Pharma Company N.V.) Current Price: $24.69 (+34.40%) Key Levels: Support $12.77 | Resistance $27.29 🚀 Strategy: Day Trade: Entry above $25.00 | Target: $26.50-$27.50 Swing Trade: Pullback to $22.50 | Target: $30.00 💥 Platinum+ / Premium join the Discord! up to -70% discount Christmas Sale 💥 💬 Join now: www.patreon.com/chartlab #Stocks #Investing #Pharma #SwingTrade #Biotech

Stocksrunner Posted - 1 week ago

Who said investing can't be a thrill? This week hottest stocks are about to blow your mind! $AVGO crushing AI expectations $CRDF making biotech waves $MIND tech triumph and $NAMS pharma breakthrough https://stocksrunner.com/posts/2024-12-14-Hottest-Stocks-of-the-Week

bullharder Posted - 1 week ago

$NAMS key factor investors fail to realize is the NAMS results were in combination with statins. My money is still on $ESPR 👍

tedevan Posted - 1 week ago

$ESPR $NAMS

Canyon_Partnerrs Posted - 1 week ago

$ESPR $8 million more a year in total interest, versus previous notes of $264 million due 12/2025. This stock should be so much higher. 2025 will be a very profitable year. NEXLIZET has lowered my LDLC by 47%. I also know it's lowered my HSCRP levels. Remember, PCSK9 drugs don't. The $NAMS drug won't ever get a primary prevention label. NEXLIZET & NEXLETOL will be 1st in choice as a statin alternative because of the primary prevention labels. Insurance companies will be push for NEXLIZET & Nexletol over other statin alternative drugs for effectiveness, cost & longevity . Ezetimibe will be prescribed a lot less because it's not effective enough by itself . NAMS drug, don't expect approval until late 2027, then Insurances will have coverage issues/ delays, until 2028 2029 says my CARDIOLOGIST. Insurance companies need to see final studies & drag 18 months after to pay for drug costs.

travisdubya Posted - 1 week ago

@foolaround $NAMS had a recent phase 3 trial that showed their product was potentially more effective than Espr’s

supasage2003 Posted - 1 week ago

@salmonbrain Sorry I misread your message. In 2024, they went 3 for 5. The mean return was 75.2% while the median return was 85.8%. The 2024 picks included $FUSN, $NAMS, $KRYS, $IONS and $CABA. The respective returns were 292.5%, 104.9%, 85.8%, -30.8% and -76.2%.

Barbell_Investment_Ideas Posted - 1 week ago

$NAMS instis buying hand over fist, retail is selling ... mhm

Barbell_Investment_Ideas Posted - 1 week ago

$NAMS most underowned/ -followed stock by retail I have seen for a long time ... lol ... superb shareholder base and 320 followers on this site ... lol

newfguy Posted - 1 week ago

$NAMS so much for dilution concerns

masonat Posted - 1 week ago

$NAMS 16.9% of patients with HeFH in the placebo group vs 16.8% in the obicetrapib group. Some smoking gun here🤦🏻‍♂️

ChartLaboratory_com Posted - 1 week ago

$NAMS 🚀 (+39.35%) 📉 Support: $24.00 | 📈 Resistance: $27.29 💥 Bullish trend confirmed with price above EMA 200. 🎯 Entry: Above $26.00 🎯 Targets: $27.29 & $30.00 🛑 Stop Loss: Below $25.00 💥 Join More Insights: www.patreon.com/chartlab - 70% OFF Black Friday Sale 🖤 #TradingIdeas #MomentumStocks #ChartLab #BlackFridaySale

Barbell_Investment_Ideas Posted - 1 week ago

$NAMS ... these $ESPR shareholders here should take some brain pills ... or maybe some anti-envy ones ... it's just ridiculous ... I dont have a clue about biotechs but just compare the shareholder base of both companies .... they are not even playing the same kind of sport ... it seems

DonCorleone77 Posted - 1 week ago

$NAMS NewAmsterdam Pharma 12.12M share Secondary priced at $24.50 The deal size was increased to $416.5M from $300M and priced below last closing price of $25.57. Jefferies, Goldman Sachs, Leerink, TD Cowen, Guggenheim and William Blair are acting as joint book running managers for the offering.

newfguy Posted - 1 week ago

$NAMS ESPR derangement syndrome is raging